Cargando…

A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals

BACKGROUND: Essential medicines are those drugs that satisfy the priority health care needs of the population and help with functioning healthcare systems. Although many countries have formulated an essential medicine list, almost half of the global population still lack regular access to essential...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xiaodong, Hu, Huajie, Man, Chunxia, Shi, Luwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194621/
https://www.ncbi.nlm.nih.gov/pubmed/30340587
http://dx.doi.org/10.1186/s12939-018-0870-5
_version_ 1783364262061670400
author Guan, Xiaodong
Hu, Huajie
Man, Chunxia
Shi, Luwen
author_facet Guan, Xiaodong
Hu, Huajie
Man, Chunxia
Shi, Luwen
author_sort Guan, Xiaodong
collection PubMed
description BACKGROUND: Essential medicines are those drugs that satisfy the priority health care needs of the population and help with functioning healthcare systems. Although many countries have formulated an essential medicine list, almost half of the global population still lack regular access to essential medicines. Research about the initiation of National Essential Medicines Policy in Chinese secondary and tertiary hospitals is inadequate, and the long-term effect on access after the reform is still unknown. This study’s objective was to investigate the access to essential medicines in mainland China’s secondary and tertiary hospitals. METHODS: Data on the access to 30 essential medicines from China’s National Essential Medicine List were obtained from China Medicine Economic Information database covering 396 secondary hospitals and 763 tertiary hospitals. We improved the standard methodology developed by the World Health Organization and the Health Action International to measure the availability, median price ratio (MPR) and the incidence of catastrophic drug expenditure (CDE). RESULTS: Five essential medicines had > 50% availability and the nationwide availability kept steady; availability of drugs in eastern regions of China was significantly higher than the central and western regions. The median MPR of 30 drugs nationwide kept steady approximately 5; MPR of drugs in the eastern regions was significantly higher than the central and western regions and the ratio of MPR of innovator brands to generics increased from 3.66 to 6.32 during the study period. The incidence of CDE caused by essential medicines decreased from 2011 to 2014; brand name medicines were more likely to cause CDE than generics and rural patients have a greater tendency to fall into CDE. CONCLUSIONS: After the implementation of National Essential Medicines Policy, the MPR of essential medicines was well controlled and became more affordable in the context of steady availability. This has highlighted the problems associated with region disparity and inequity between rural and urban areas in the delivery of essential medicines and sustainable mechanisms are needed to deepen the National Essential Medicines Policy in mainland China. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12939-018-0870-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6194621
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61946212018-10-25 A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals Guan, Xiaodong Hu, Huajie Man, Chunxia Shi, Luwen Int J Equity Health Research BACKGROUND: Essential medicines are those drugs that satisfy the priority health care needs of the population and help with functioning healthcare systems. Although many countries have formulated an essential medicine list, almost half of the global population still lack regular access to essential medicines. Research about the initiation of National Essential Medicines Policy in Chinese secondary and tertiary hospitals is inadequate, and the long-term effect on access after the reform is still unknown. This study’s objective was to investigate the access to essential medicines in mainland China’s secondary and tertiary hospitals. METHODS: Data on the access to 30 essential medicines from China’s National Essential Medicine List were obtained from China Medicine Economic Information database covering 396 secondary hospitals and 763 tertiary hospitals. We improved the standard methodology developed by the World Health Organization and the Health Action International to measure the availability, median price ratio (MPR) and the incidence of catastrophic drug expenditure (CDE). RESULTS: Five essential medicines had > 50% availability and the nationwide availability kept steady; availability of drugs in eastern regions of China was significantly higher than the central and western regions. The median MPR of 30 drugs nationwide kept steady approximately 5; MPR of drugs in the eastern regions was significantly higher than the central and western regions and the ratio of MPR of innovator brands to generics increased from 3.66 to 6.32 during the study period. The incidence of CDE caused by essential medicines decreased from 2011 to 2014; brand name medicines were more likely to cause CDE than generics and rural patients have a greater tendency to fall into CDE. CONCLUSIONS: After the implementation of National Essential Medicines Policy, the MPR of essential medicines was well controlled and became more affordable in the context of steady availability. This has highlighted the problems associated with region disparity and inequity between rural and urban areas in the delivery of essential medicines and sustainable mechanisms are needed to deepen the National Essential Medicines Policy in mainland China. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12939-018-0870-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-19 /pmc/articles/PMC6194621/ /pubmed/30340587 http://dx.doi.org/10.1186/s12939-018-0870-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Guan, Xiaodong
Hu, Huajie
Man, Chunxia
Shi, Luwen
A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals
title A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals
title_full A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals
title_fullStr A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals
title_full_unstemmed A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals
title_short A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals
title_sort survey of availability, price and affordability of essential medicines from 2011 to 2016 in chinese secondary and tertiary hospitals
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194621/
https://www.ncbi.nlm.nih.gov/pubmed/30340587
http://dx.doi.org/10.1186/s12939-018-0870-5
work_keys_str_mv AT guanxiaodong asurveyofavailabilitypriceandaffordabilityofessentialmedicinesfrom2011to2016inchinesesecondaryandtertiaryhospitals
AT huhuajie asurveyofavailabilitypriceandaffordabilityofessentialmedicinesfrom2011to2016inchinesesecondaryandtertiaryhospitals
AT manchunxia asurveyofavailabilitypriceandaffordabilityofessentialmedicinesfrom2011to2016inchinesesecondaryandtertiaryhospitals
AT shiluwen asurveyofavailabilitypriceandaffordabilityofessentialmedicinesfrom2011to2016inchinesesecondaryandtertiaryhospitals
AT guanxiaodong surveyofavailabilitypriceandaffordabilityofessentialmedicinesfrom2011to2016inchinesesecondaryandtertiaryhospitals
AT huhuajie surveyofavailabilitypriceandaffordabilityofessentialmedicinesfrom2011to2016inchinesesecondaryandtertiaryhospitals
AT manchunxia surveyofavailabilitypriceandaffordabilityofessentialmedicinesfrom2011to2016inchinesesecondaryandtertiaryhospitals
AT shiluwen surveyofavailabilitypriceandaffordabilityofessentialmedicinesfrom2011to2016inchinesesecondaryandtertiaryhospitals